Do BTK Inhibitors Lead to Secondary Cancers?


Patients with CLL prescribed BTK inhibitors may have a higher chance of developing secondary cancers, according to recent research.

Patients with chronic lymphocytic leukemia who take BTK inhibitors tend to have a higher rate of secondary cancers than the general population, explained David A. Bond, MD, an assistant professor at The Ohio State University.

In a study including 691 patients, Bond and his team catalogued secondary cancer instances, and found that these diagnoses were the second leading cause of death in the population.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.